既往黏菌素治疗与否对黏菌素耐药鲍曼不动杆菌临床分离株的差异
结果显示两组临床特征无差异,但治疗组基因突变更频繁;Sanger测序可能因敏感亚群掩盖而遗漏突变,而脂质A分析可检测耐药峰且组间差异显著。结论认为测序鉴定CR-AB不足,建议采用反映细菌生理改变的准确方法。
要点
- 既往黏菌素治疗未导致临床特征或药敏差异,但耐药基因突变更常见。
- Sanger测序可能因敏感亚群掩盖而遗漏耐药突变。
- 脂质A分析可检测耐药峰,组间差异显著,建议用于准确鉴定。
核心结论
- 既往黏菌素使用未引起临床或药敏差异,但基因突变更频繁。
- 测序鉴定CR-AB不足,群体异质性可产生掩盖效应。
- 建议采用反映细菌生理改变的准确方法,如MALDI-TOF鉴定磷酸乙醇胺修饰的脂质A。
研究设计与样本
- 进行抗菌药物敏感性试验、Sanger测序分析、分子分型、脂质A结构分析和体外协同试验。
主要发现
- 既往治疗组与未治疗组临床特征无差异。
- 耐药相关基因突变在既往黏菌素治疗患者分离株中更频繁。
- Sanger测序可能因缺乏突变的敏感亚群掩盖而遗漏独特突变。
- 脂质A分析显示耐药峰,尽管存在群体异质性,且峰水平组间显著不同。
关键数值与推荐
- 36株非重复CR-AB临床分离株对黏菌素耐药。
临床怎么用
- 不应仅依赖Sanger测序鉴定CR-AB。
- 对于黏菌素未治疗患者,需考虑群体异质性掩盖效应。
- 建议采用MALDI-TOF鉴定磷酸乙醇胺修饰的脂质A等反映生理改变的方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increasing morbidity and mortality rates associated with Acinetobacter baumannii are due to the emergence of drug resistance and the limited treatment options. We compared characteristics of colistin-resistant Acinetobacter baumannii (CR-AB) clinical isolates recovered from patients with and without prior colistin treatment. We assessed whether prior colistin treatment affects the resistance mechanism of CR-AB isolates, mortality rates, and clinical characteristics. Additionally, a proper method for identifying CR-AB was determined. METHODS: We collected 36 non-duplicate CR-AB clinical isolates resistant to colistin. Antimicrobial susceptibility testing, Sanger sequencing analysis, molecular typing, lipid A structure analysis, and in vitro synergy testing were performed. Eleven colistin-susceptible AB isolates were used as controls. RESULTS: Despite no differences in clinical characteristics between patients with and without prior colistin treatment, resistance-causing genetic mutations were more frequent in isolates from colistin-treated patients. Distinct mutations were overlooked via the Sanger sequencing method, perhaps because of a masking effect by the colistin-susceptible AB subpopulation of CR-AB isolates lacking genetic mutations. However, modified lipid A analysis revealed colistin resistance peaks, despite the population heterogeneity, and peak levels were significantly different between the groups. CONCLUSIONS: Although prior colistin use did not induce clinical or susceptibility differences, we demonstrated that identification of CR-AB by sequencing is insufficient. We propose that population heterogeneity has a masking effect, especially in colistin non-treated patients; therefore, accurate testing methods reflecting physiological alterations of the bacteria, such as phosphoethanolamine-modified lipid A identification by matrix-assisted laser desorption ionization-time of flight, should be employed.
引用
- Park YJ, Hong DJ, Yoon EJ, et al. Differences in Colistin-resistant Acinetobacter baumannii Clinical Isolates Between Patients With and Without Prior Colistin Treatment. Ann Lab Med. 2018. PMID: 30027698. doi:10.3343/alm.2018.38.6.545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。